Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Breast Neoplasms × eribulin × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 94 Observational 8 Expanded_access 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

abemaciclib 2 zenocutuzumab 1 tucatinib 1 selpercatinib 1 ribociclib 1 pegilodecakin 1 iniparib 1 eribulin 1 Proton Pump Inhibitors 1 Hydrocortisone 1 Everolimus 1 Alpelisib 1 Ado-Trastuzumab Emtansine 1 AM0010 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01240421 2015-05-22

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Eisai Inc.

Approved for marketing

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡